Repertoire Immune Medicines entered a strategic collaboration on Thursday with Eli Lilly and Co. (NYSE:LLY) to develop tolerizing therapies for multiple autoimmune diseases. • Eli Lilly and Co stock is showing positive momentum. Where are LLY shares going?Repertoire Immune is a biotechnology company focused on the discovery and development of programmable T cell-targeted immune medicines.Under the terms of the agreement, Repertoire will receive an upfront payment of $85 million and up to an additional $1.84 ...